Loading…

Update in venous thromboembolism in cancer: Lessons from multi-centre registries

Cancer-associated thrombosis is a common problem in cancer patients and one of the leading causes of death in this population. Randomised clinical trials have shown that both low-molecular-weight heparins and direct oral anticoagulants are the treatments of choice for cancer-associated thrombosis. D...

Full description

Saved in:
Bibliographic Details
Published in:Thrombosis update 2024-09, Vol.16, p.100183, Article 100183
Main Authors: Soto Alsar, Javier, Jiménez Rodríguez, Roberto, Gutiérrez, Ana, Ortega Morán, Laura, Muñoz Martín, Andrés J.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c2033-dd3d3a9c26645b0d9aaeb3abd71c0357acf35bcb5a4e1efe64c697851bd29cca3
container_end_page
container_issue
container_start_page 100183
container_title Thrombosis update
container_volume 16
creator Soto Alsar, Javier
Jiménez Rodríguez, Roberto
Gutiérrez, Ana
Ortega Morán, Laura
Muñoz Martín, Andrés J.
description Cancer-associated thrombosis is a common problem in cancer patients and one of the leading causes of death in this population. Randomised clinical trials have shown that both low-molecular-weight heparins and direct oral anticoagulants are the treatments of choice for cancer-associated thrombosis. Despite this, small sample sizes, poor representation of some patient subgroups and lack of information about real-world clinical situations are some of the limitations of randomised trials. To overcome these problems, registries have been established to collect real-world data from patients with cancer-associated thrombosis, offering new evidence and information to supplement the findings of randomised clinical trials. However, few registries have focused exclusively on cancer patients, and some have excluded various subgroups of patients. Additionally, data collection and processing are another major challenge in analysing registry results, where the emergence of artificial intelligence will play a fundamental role. •CAT registries are scarce and few of them are specific for cancer patients.•RIETE is the largest registry to date but not cancer-specific.•GARFIELD includes less patients than RIETE but with longer follow-up.•TESEO is the only cancer-specific registry that includes all types of tumours, with a longer follow-up.
doi_str_mv 10.1016/j.tru.2024.100183
format article
fullrecord <record><control><sourceid>elsevier_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_c0f5d63703ca4aa9a6317998b2f96000</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2666572724000257</els_id><doaj_id>oai_doaj_org_article_c0f5d63703ca4aa9a6317998b2f96000</doaj_id><sourcerecordid>S2666572724000257</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2033-dd3d3a9c26645b0d9aaeb3abd71c0357acf35bcb5a4e1efe64c697851bd29cca3</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRSMEEhX0A9jlB1LsOHFiWKGKR6VKsKBrazKeFEd5VLZbib_HpQixYjHyjD336vokyQ1nC864vO0Wwe0XOcuLODNei7Nklksps7LKq_M__WUy975jjOV1XJT1LHnb7AwESu2YHmic9j4NH24amoli9dYPxxeEEcndpWvyfhp92saNdNj3wWZIY3CUOtpaH5wlf51ctNB7mv-cV8nm6fF9-ZKtX59Xy4d1hjkTIjNGGAEKY7SibJhRANQIaEzFkYmyAmxF2WBTQkGcWpIFSlXVJW9MrhBBXCWrk6-ZoNM7Zwdwn3oCq78vJrfV4ILFnjSytjRSVEwgFAAKpOCVUnWTt0pGGNGLn7zQTd47an_9ONNHwrrTkbA-EtYnwlFzf9JQ_OTBktMeLUVOxjrCEFPYf9RfJmyE1w</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Update in venous thromboembolism in cancer: Lessons from multi-centre registries</title><source>ScienceDirect Journals</source><creator>Soto Alsar, Javier ; Jiménez Rodríguez, Roberto ; Gutiérrez, Ana ; Ortega Morán, Laura ; Muñoz Martín, Andrés J.</creator><creatorcontrib>Soto Alsar, Javier ; Jiménez Rodríguez, Roberto ; Gutiérrez, Ana ; Ortega Morán, Laura ; Muñoz Martín, Andrés J.</creatorcontrib><description>Cancer-associated thrombosis is a common problem in cancer patients and one of the leading causes of death in this population. Randomised clinical trials have shown that both low-molecular-weight heparins and direct oral anticoagulants are the treatments of choice for cancer-associated thrombosis. Despite this, small sample sizes, poor representation of some patient subgroups and lack of information about real-world clinical situations are some of the limitations of randomised trials. To overcome these problems, registries have been established to collect real-world data from patients with cancer-associated thrombosis, offering new evidence and information to supplement the findings of randomised clinical trials. However, few registries have focused exclusively on cancer patients, and some have excluded various subgroups of patients. Additionally, data collection and processing are another major challenge in analysing registry results, where the emergence of artificial intelligence will play a fundamental role. •CAT registries are scarce and few of them are specific for cancer patients.•RIETE is the largest registry to date but not cancer-specific.•GARFIELD includes less patients than RIETE but with longer follow-up.•TESEO is the only cancer-specific registry that includes all types of tumours, with a longer follow-up.</description><identifier>ISSN: 2666-5727</identifier><identifier>EISSN: 2666-5727</identifier><identifier>DOI: 10.1016/j.tru.2024.100183</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><subject>Cancer-associated thrombosis ; randomised clinical trials ; Real world data ; Real world evidence ; Registries</subject><ispartof>Thrombosis update, 2024-09, Vol.16, p.100183, Article 100183</ispartof><rights>2024 The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2033-dd3d3a9c26645b0d9aaeb3abd71c0357acf35bcb5a4e1efe64c697851bd29cca3</cites><orcidid>0009-0009-8859-5881</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2666572724000257$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3549,27924,27925,45780</link.rule.ids></links><search><creatorcontrib>Soto Alsar, Javier</creatorcontrib><creatorcontrib>Jiménez Rodríguez, Roberto</creatorcontrib><creatorcontrib>Gutiérrez, Ana</creatorcontrib><creatorcontrib>Ortega Morán, Laura</creatorcontrib><creatorcontrib>Muñoz Martín, Andrés J.</creatorcontrib><title>Update in venous thromboembolism in cancer: Lessons from multi-centre registries</title><title>Thrombosis update</title><description>Cancer-associated thrombosis is a common problem in cancer patients and one of the leading causes of death in this population. Randomised clinical trials have shown that both low-molecular-weight heparins and direct oral anticoagulants are the treatments of choice for cancer-associated thrombosis. Despite this, small sample sizes, poor representation of some patient subgroups and lack of information about real-world clinical situations are some of the limitations of randomised trials. To overcome these problems, registries have been established to collect real-world data from patients with cancer-associated thrombosis, offering new evidence and information to supplement the findings of randomised clinical trials. However, few registries have focused exclusively on cancer patients, and some have excluded various subgroups of patients. Additionally, data collection and processing are another major challenge in analysing registry results, where the emergence of artificial intelligence will play a fundamental role. •CAT registries are scarce and few of them are specific for cancer patients.•RIETE is the largest registry to date but not cancer-specific.•GARFIELD includes less patients than RIETE but with longer follow-up.•TESEO is the only cancer-specific registry that includes all types of tumours, with a longer follow-up.</description><subject>Cancer-associated thrombosis</subject><subject>randomised clinical trials</subject><subject>Real world data</subject><subject>Real world evidence</subject><subject>Registries</subject><issn>2666-5727</issn><issn>2666-5727</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9kMtOwzAQRSMEEhX0A9jlB1LsOHFiWKGKR6VKsKBrazKeFEd5VLZbib_HpQixYjHyjD336vokyQ1nC864vO0Wwe0XOcuLODNei7Nklksps7LKq_M__WUy975jjOV1XJT1LHnb7AwESu2YHmic9j4NH24amoli9dYPxxeEEcndpWvyfhp92saNdNj3wWZIY3CUOtpaH5wlf51ctNB7mv-cV8nm6fF9-ZKtX59Xy4d1hjkTIjNGGAEKY7SibJhRANQIaEzFkYmyAmxF2WBTQkGcWpIFSlXVJW9MrhBBXCWrk6-ZoNM7Zwdwn3oCq78vJrfV4ILFnjSytjRSVEwgFAAKpOCVUnWTt0pGGNGLn7zQTd47an_9ONNHwrrTkbA-EtYnwlFzf9JQ_OTBktMeLUVOxjrCEFPYf9RfJmyE1w</recordid><startdate>202409</startdate><enddate>202409</enddate><creator>Soto Alsar, Javier</creator><creator>Jiménez Rodríguez, Roberto</creator><creator>Gutiérrez, Ana</creator><creator>Ortega Morán, Laura</creator><creator>Muñoz Martín, Andrés J.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>DOA</scope><orcidid>https://orcid.org/0009-0009-8859-5881</orcidid></search><sort><creationdate>202409</creationdate><title>Update in venous thromboembolism in cancer: Lessons from multi-centre registries</title><author>Soto Alsar, Javier ; Jiménez Rodríguez, Roberto ; Gutiérrez, Ana ; Ortega Morán, Laura ; Muñoz Martín, Andrés J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2033-dd3d3a9c26645b0d9aaeb3abd71c0357acf35bcb5a4e1efe64c697851bd29cca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cancer-associated thrombosis</topic><topic>randomised clinical trials</topic><topic>Real world data</topic><topic>Real world evidence</topic><topic>Registries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Soto Alsar, Javier</creatorcontrib><creatorcontrib>Jiménez Rodríguez, Roberto</creatorcontrib><creatorcontrib>Gutiérrez, Ana</creatorcontrib><creatorcontrib>Ortega Morán, Laura</creatorcontrib><creatorcontrib>Muñoz Martín, Andrés J.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>Directory of Open Access Journals</collection><jtitle>Thrombosis update</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Soto Alsar, Javier</au><au>Jiménez Rodríguez, Roberto</au><au>Gutiérrez, Ana</au><au>Ortega Morán, Laura</au><au>Muñoz Martín, Andrés J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Update in venous thromboembolism in cancer: Lessons from multi-centre registries</atitle><jtitle>Thrombosis update</jtitle><date>2024-09</date><risdate>2024</risdate><volume>16</volume><spage>100183</spage><pages>100183-</pages><artnum>100183</artnum><issn>2666-5727</issn><eissn>2666-5727</eissn><abstract>Cancer-associated thrombosis is a common problem in cancer patients and one of the leading causes of death in this population. Randomised clinical trials have shown that both low-molecular-weight heparins and direct oral anticoagulants are the treatments of choice for cancer-associated thrombosis. Despite this, small sample sizes, poor representation of some patient subgroups and lack of information about real-world clinical situations are some of the limitations of randomised trials. To overcome these problems, registries have been established to collect real-world data from patients with cancer-associated thrombosis, offering new evidence and information to supplement the findings of randomised clinical trials. However, few registries have focused exclusively on cancer patients, and some have excluded various subgroups of patients. Additionally, data collection and processing are another major challenge in analysing registry results, where the emergence of artificial intelligence will play a fundamental role. •CAT registries are scarce and few of them are specific for cancer patients.•RIETE is the largest registry to date but not cancer-specific.•GARFIELD includes less patients than RIETE but with longer follow-up.•TESEO is the only cancer-specific registry that includes all types of tumours, with a longer follow-up.</abstract><pub>Elsevier Ltd</pub><doi>10.1016/j.tru.2024.100183</doi><orcidid>https://orcid.org/0009-0009-8859-5881</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2666-5727
ispartof Thrombosis update, 2024-09, Vol.16, p.100183, Article 100183
issn 2666-5727
2666-5727
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_c0f5d63703ca4aa9a6317998b2f96000
source ScienceDirect Journals
subjects Cancer-associated thrombosis
randomised clinical trials
Real world data
Real world evidence
Registries
title Update in venous thromboembolism in cancer: Lessons from multi-centre registries
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A14%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Update%20in%20venous%20thromboembolism%20in%20cancer:%20Lessons%20from%20multi-centre%20registries&rft.jtitle=Thrombosis%20update&rft.au=Soto%20Alsar,%20Javier&rft.date=2024-09&rft.volume=16&rft.spage=100183&rft.pages=100183-&rft.artnum=100183&rft.issn=2666-5727&rft.eissn=2666-5727&rft_id=info:doi/10.1016/j.tru.2024.100183&rft_dat=%3Celsevier_doaj_%3ES2666572724000257%3C/elsevier_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2033-dd3d3a9c26645b0d9aaeb3abd71c0357acf35bcb5a4e1efe64c697851bd29cca3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true